MNA
VRTX icon

Manning & Napier Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Manning & Napier Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
2,064
-218,525
-99% -$96.8M 0.01% 241
2026
Q1 		$98.5M Sell
220,589
-207,014
-48% -$96.5M 1.39% 22
2025
Q4 		$194M Sell
427,603
-47,219
-10% -$20.4M 2.52% 7
2025
Q3 		$188M Buy
474,822
+241,242
+103% +$101M 2.39% 12
2025
Q2 		$104M Sell
233,580
-1,528
-0.6% -$704K 1.24% 29
2025
Q1 		$114M Buy
235,108
+84,982
+57% +$39.6M 1.41% 22
2024
Q4 		$60.5M Sell
150,126
-5,635
-4% -$2.61M 0.69% 45
2024
Q3 		$72.4M Sell
155,761
-2,571
-2% -$1.24M 0.8% 37
2024
Q2 		$74.2M Buy
+158,332
New +$68.7M 0.84% 42
2017
Q3 		$135M Sell
885,868
-745,258
-46% -$112M 1.15% 32
2017
Q2 		$210M Sell
1,631,126
-133,293
-8% -$16M 1.81% 16
2017
Q1 		$193M Sell
1,764,419
-361,601
-17% -$31.8M 1.5% 23
2016
Q4 		$157M Buy
2,126,020
+1,983,480
+1,392% +$161M 1.02% 39
2016
Q3 		$12.4M Buy
142,540
+15,550
+12% +$1.47M 0.08% 98
2016
Q2 		$10.9M Buy
+126,990
New +$11M 0.07% 111

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Manning & Napier Advisors's VRTX Position: Q2 2026 in Review

Manning & Napier Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 99% in Q2 2026, selling an estimated $96.8M and leaving 2,064 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #241.

Manning & Napier Advisors first reported a position in VRTX in Q2 2016 and has held it in 15 quarters since. The position peaked at $210M in Q2 2017. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Manning & Napier Advisors held 2,064 shares of Vertex Pharmaceuticals worth $1.03M as of Q2 2026.
  • Manning & Napier Advisors sold 218,525 Vertex Pharmaceuticals shares in Q2 2026, an estimated $96.8M.
  • Vertex Pharmaceuticals made up 0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #241 holding.
  • Manning & Napier Advisors first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • Manning & Napier Advisors's Vertex Pharmaceuticals position peaked at $210M in Q2 2017.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.